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In non-small cell lung cancer (NSCLC), nodal metastasis is an adverse prognostic factor.
Several mediating factors have been implied in the development of nodal metastases and
investigated for predictive and prognostic properties in NSCLC. However, study results dif-
fer. In this structured review and meta-analysis we explore the published literature on com-
monly recognized pathways for molecular regulation of lymphatic metastasis in NSCLC.
Methods
A structured PubMed search was conducted for papers reporting on the expression of
known markers of lymhangiogenesis in NSCLC patients. Papers of sufficient quality, pre-
senting survival and/or correlation data were included.
Results
High levels of vascular endothelial growth factor C (VEGF-C, HR 1.57 95% CI 1.34–1.84)
and high lymphatic vascular density (LVD, HR 1.84 95% CI 1.18–2.87) were significant
prognostic markers of poor survival and high expression of VEGF-C, vascular endothelial
growth factor receptor 3 (VEGFR3) and LVD was associated with lymph node metastasis in
NSCLC.
Conclusion
Lymphangiogenic markers are prognosticators of survival and correlate with lymph node
metastasis in NSCLC. Their exact role and clinical implications should be further elucidated.
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Introduction
Lung cancer is estimated to have the second highest incidence of all cancers in US women and
men [1]. With a dismal prognosis, and over 163 000 expected deaths in 2014, lung cancer is the
number one killer amongst cancers [1]. Lung cancer is staged according to the system advo-
cated by the American Joint Committee on Cancer (AJCC) and the Union Internationale
Contre le Cancer (UICC) which as of 2010 is in its 7th edition [2,3]. The system is built around
tumor size and localization (T), extent of nodal involvement (N) and presence of distant metas-
tasis (M) [3]. In short, stage I comprises small localized tumors, while stages II-IIIA represent
larger tumors with or without nodal metastasis [3]. The five-year-survival for stage IA, IB, IIA,
IIB and IIIA lung cancer is 65–81%, 54–72%, 46–59%, 46–47% and 33–38% respectively [4–6].
Stage IIIB and IV lung cancers are not considered for surgery and have an abysmal prognosis
[4–6]. Non-small cell lung cancer (NSCLC) represent>80% of all lung cancer cases [7].
Nodal metastasis represents a major shift in NSCLC biology, from a localized to an invasive
phenotype. Patients presenting with nodal metastases have a more advanced stage and a worse
prognosis compared to patients without nodal involvement and the same tumor size [3]. Fur-
ther, the prognosis of patients radically operated for stage I NSCLC differs widely, with 20–
35% of patients developing recurrent disease, often in localized lymph nodes [4–6,8]. Vascular
endothelial growth factors (VEGF) -C and -D, and their corresponding receptor vascular endo-
thelial growth factor receptor 3 (VEGFR3, also known as Flt4), are by many considered the
main players in the development of tumor associated lymphatic vessels [9]. These work by
recruiting endothelial cells (ECs) and other stromal cells to develop and maintain a crude lym-
phatic network in the tumor micro-environment [9,10]. In tumor models of NSCLC, the pres-
ence of VEGF-C and VEGFR3 leads to proliferation, invasiveness and nodal metastases [11].
There is also evidence supporting that tumor derived VEGF-C induces the development of
lymphatic vasculature in premetastatic lymph nodes; thus preparing them for the arrival and
hosting of cancer cells [12,13]. The inhibition of VEGFR3 in a xenograft model of NSCLC indi-
cated that abrogation of lymphangiogenesis could prevent lymphatic metastasis [14]. Interest-
ingly, anti-VEGFR3 treatment had to be initiated before the development of lymphatic
vasculature for its effect to take place and it did not abrogate lymphatic vessel co-option [14].
Lymphatic vessel density (LVD) represent the density of lymphatic vessels in the tumor
micro-environment. For many cancers LVD is an established marker of adverse prognosis, but
no real consensus regarding its evaluation exist [15–18]. A connection between tumor
VEGF-C expression and LVD in sentinel lymph nodes has been suggested [19]. In NSCLC, the
expression of VEGF-C [20–28], VEGF-D [21,22,29] and VEGFR3 [30] as well as lymphatic
vessel density (LVD) [21,23,28,31–33] have been correlated to nodal metastasis and linked to
patient survival. Intriguingly, other studies fail to show these relationships.
Herein we present a structured review and meta-analysis of lymphangiogenesis and its rela-
tionship with lymph node metastasis and survival in NSCLC with emphasis on VEGF-C,
VEGF-D, VEGFR3 and LVD.
Materials and Methods
Search strategy and study selection
The electronic database MEDLINE was searched for studies reported up to a date limit set to
Sept. 22, 2014 with no lower date limit applied. The search string used for lymphangiogenesis
was ((lymphatic vessel density) OR (LVD) OR (lymphatic micro vessel density) OR (LMVD)
OR (D2-40) OR (VEGFR3) OR (flt4) OR (VEGF-C) OR (CD34)) AND ((non-small cell lung
cancer) OR (non small lung cell cancer) OR (non-small lung cell cancer) OR (NSCLC) OR
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(adenocarcinoma of the lung) OR (lung adenocarcinoma) OR (squamous cell carcinoma of the
lung) OR (lung squamous cell carcinoma) OR (lung SCC) OR (large-cell carcinoma of the lung)
OR (lung large-cell carcinoma) OR (lung LCC)) AND (Humans[Mesh] AND English[lang]).
The searches were restricted to human species and English language. Publications selected
for full reading were explored to complete the searches.
Inclusion criteria for the meta-analyses were as follows: (1) measure of VEGF-C, VEGF-D
or VEGFR3 in primary NSCLC tissue using immunohistochemistry (IHC) or enzyme linked
immunosorbent assay (ELISA)/reverse transcription-polymerase chain reaction (RT-PCR) or a
measure of LVD; (2) providing survival information in the form of HR with 95% CI OR num-
bers with high/low expression and survival curves OR correlation with lymphatic metastasis
and sufficient data to calculate RR; (3) follow-up exceeding two years; (4) only the most recent
OR most adequate publication was used in the case of the same author reporting on the same
population. Two reviewers (T. K and T. D) independently determined the study eligibility of
publications selected for full reading, with disagreement resolved by consensus.
Data extraction and quality assessment
The eligible studies were assessed by two independent reviewers (T. K and T. D). The data
retrieved from each study included author(s), test method, cut-off and data on survival and/or
lymphatic metastasis. In the case of missing data the author of the primary study was contacted
using the email address supplied in the original publication, missing data not supplied by the
authors were extracted from the summary statistics where possible.
To assess the overall quality of studies included in the meta-analysis, these were scored
according to a modified quality scale for biological prognostic factors for lung cancer developed
by Steels et al. for the European Lung Cancer Working Group [34]. The quality scale incorpo-
rates four dimensions of method assessment 1) Scientific design (5 questions); 2) Laboratory
methodology (7 questions); 3) Generalizability (6 questions); 4) Results analysis (4 questions).
All questions were scored using an ordinal scale (values: 2, 1, 0), with results given as percent-
ages of achievable points within each category [34].
Statistical analyses
All analyses were conducted in R-studio version 0.98.1087 using R-kernel 3.1.1.
For the meta-analyses of markers in relation to survival endpoints, univariate hazard ratios
(HR) with corresponding 95% confidence intervals (CI) were combined to give the aggregated
effect estimates. For cases in which these values were not reported, or supplied from the author
(s) upon request, the data were extrapolated from available numerical data and survival curves
according to methods described by Parmar et. al [35]. For cases in which survival curves were
used, these were first digitalized using Engauge digitizer [36]. For the analysis of survival curves
constant censoring during the follow-up of survivors were assumed. A 3-month interval
between censoring calculations was deemed adequate. For papers with overall survival as end-
point censoring was assumed to start at the time of minimum follow-up. For papers based on
disease-specific survival censoring was assumed to start at patient inclusion. Maximal follow-
up was set to the difference between minimum follow-up and the date of last follow-up. For
papers where the date of the last follow-up was not given these dates were extrapolated from
the survival curves.
For the meta-analyses of markers in relation to nodal metastasis, data was extracted in the
form of 2x2 tables from which the effect estimates were calculated.
Aggregation of data was conducted using the R-package “metafor” [37]. A certain level of
heterogeneity was expected and because of this, a random effects model was used to estimate
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the HRs and corresponding 95% CIs. Overall heterogeneity was examined using Q, tau 2, I2
and H2 statistics [38]. To explore the heterogeneity introduced by each study included in the
meta-analyses, a function leaving out one article at a time (leave1out in the “metaphor” pack-
age) was used. Subgroup analyses, according to stage and histology, (adenocarcinoma or squa-
mous cell carcinoma) were conducted for markers where sufficient information was provided.
Egger's test was used to evaluate publication bias [39]. Contour enhanced funnel plot's were
used to help interpret, and to further explore publication bias in the case of funnel asymmetry
[40]. The trim and fill method was used to visualize and to adjust for missing studies in the
case of publication bias [41].
Results
Study selection and characteristics
Fig 1 summarizes the search strategy and inclusion processes. Three-hundred-and-forty-seven
studies were identified in the initial search with an additional eight studies identified from
reading bibliographies. After initial screening 42 studies were selected for full review [20–
33,42–70]. The articles selected for full review and subsequently included in the meta-analyses
are summarized in Table 1. As expected several papers reported on more than one lymphan-
giogenic marker.
Thirty studies reported survival data for VEGF-C (23), VEGF-D(4), VEGFR3(9) and LVD
(13) [23,24,28,29,31,32,42–51,54–58,61–66,68–70]. Of these 17, four, five and eight studies
Fig 1. Illustration of the literature search and inclusion processes. Abbreviations: VEGF, vascular
endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; LVD, lymphatic vascular
density.
doi:10.1371/journal.pone.0132481.g001
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Table 1. Summarizing the studies included in the meta-analyses.
Study Year N Design Histology Stage Method Marker Positive Cut-off Survival LNM QS QS
HRe HR (95% CI) RR (95% CI) Surv LNM
Adachi et al.[21] 2007 76 Retro All I-IIIb IHC VEGF-C 20% 10% 2.85(1.3–6.2) 0.54
VEGF-D 36% 50% 3.33(1.4–8.0)
LVD 34% 20 4.81(2.1–
10.9)
Arinaga et al.[43] 2003 180 Retro All I-III IHC VEGF-C 76% 30% Surv 1.52(0.8–2.5) 0.66
VEGFR3 22% CS Surv 2.37(1.5–3.2)
Chen et al.[47] 2011 49 Retro All I IHC VEGF-C 49% CS Surv 0.94(0.0–
426.2)
0.72
Carilla de Santa et al. 2009 48 Retro All I-IV IHC VEGF-C 29% CS Surv 2.51(1.1–5.7) 0.67
[44] VEGF-D 23% CS Surv 0.55(0.2–1.8)
VEGFR3 42% CS Surv 0.54(0.2–1.3)
Donnem et al.[30,70] 2007/ 335 Retro All I-IIIa IHC VEGF-C 31% CS HR 1.30(0.9–1.8) 1.14(0.8–1.6) 0.83 0.8
2009 VEGF-D 68% CS HR 1.27(0.9–1.9) 1.25(0.9–1.8)
* VEGFR3 36% CS HR 1.69(1.2–2.4) 1.56(1.1–2.2)
Enatsu et al.[48] 2006 78 Retro Adeno I-III IHC VEGF-C 42% 10% HR 0.47(0.1–1.6) 0.58
Faoro et.al.[49] 2008 77 Retro All I-IV IHC LVD 48% Mean Surv 0.88(0.5–1.7) 0.59
Feng et al.[22] 2010 96 Retro All I-IIIa IHC, VEGF-C 44% 30% 1.41(0.9–2.2) 0.57
RT-PCR VEGF-D 24% 30% 0.93(0.6–1.6)
Guo et al.[23] 2009 65 Retro All I-IV IHC VEGF-C 77% CS 9.90(1.5–
66.5)
0.64 0.59
LVD 46% 28 Surv 1.97(1.0–3.8) 6.77(3.0–
15.3)
Huang et al.[50] 2005 97 Retro All I IHC VEGF-C 40% 30% Surv 2.45(0.8–7.1) 0.75
76 II-III 45% 0.91(0.5–1.7)
Iwakiri et al.[51] 2009 215 Retro All I-IIIa IHC LVD 51% 38 Surv 2.13(0.9–5.0) 1.05(0.7–1.5) 0.77 0.76
Kadota et al.[54] 2008 147 Retro All I-III IHC VEGF-C 44% 30% HR 1.82(1.1–3.5) 0.79
LVD 44% 15 HR 1.77(1.0–3.1)
Kajita et al.[24] 2001 62 Retro All I-IV IHC VEGF-C 39% CS Surv 2.53(0.9–7.1) 2.02(1.1–3.7) 0.59 0.55
Ko et al.[29] 2008 118 Retro All I-III IHC VEGF-C 60% CS Surv 1.21(0.6–2.5) 0.64
VEGF-D 53% CS Surv 1.11(0.5–2.4)
Kojima et al.[55] 2005 129 Retro All I-IIIb IHC VEGF-C 43% CS HR 2.72(1.4–5.4) 1.83(0.9–3.8) 0.76 0.69
VEGFR3 57% CS HR 3.04(1.5–6.7) 2.30(1.0–5.4)
Li et al.[31] 2003 76 Retro All I-IV IHC VEGF-C 72% 10% Surv 3.12(1.4–6.8) 0.47
Li et al.[20] 2010 70 Retro All I-IIIb IHC VEGF-C 70% CS 2.46(1.0–6.3) 0.61
Maekawa et al.[56] 2007 55 Retro All I RT-PCR VEGF-C NG Mean HR 2.31(0.5–10.0) 0.52
VEGF-D NG Mean HR 0.29(0.1–0.9)
VEGFR3 NG Mean HR 0.37(0.0–2.8)
Min et al.[57] 2011 97 Retro All I-III IHC LVD 70% 6 Surv 0.49(0.1–1.9) 1.03(0.5–2.0) 0.65 0.62
Nakashima et al.[58] 2004 153 Retro All I-IIIb IHC VEGF-C 42% 30% Surv 1.48(0.8–2.7) 0.98(0.6–1.4) 0.77 0.74
Ogawa et al.[61] 2004 206 Retro All I-IIIb IHC VEGF-C 61% CS Surv 1.37(0.8–2.3) 0.94(0.6–1.4) 0.65 0.58
Ohta et al.[62] 2000 122 Retro All I IHC VEGF-C 45% CS HR 1.34(0.6–3.1) 3.62(1.8–6.9) 0.68 0.63
Renyi-vamos et al.
[63]
2005 103 Retro All I-IIIa IHC LVD 50% Median Surv 2.29(1.2–4.4) 0.69 0.64
VEGF-C 56% 30% 0.99(0.7–1.5)
Saintigny et al.[64] 2007 92 Prosp All I-III IHC VEGF-C 74% CS 1.63(0.9–3.0) 0.69
VEGFR3 42% CS 1.86(1.2–2.8)
Su et al.[65] 2004 59 Retro Adeno I-IV IHC VEGF-C 49% CS Surv 1.69(1.0–3.0) 0.59
(Continued)
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included sufficient survival data and were included in the aggregated survival-analyses of
VEGF-C [24,29,31,43,44,47,48,50,54–56,58,61,62,65,69,70] VEGF-D [29,44,56,70], VEGFR3
[43,44,55,56,70] and LVD [23,28,49,51,54,57,63,66] respectively, reporting on a total of 2185,
567, 825 and 849 patients.
Thirty studies reported correlations between nodal metastasis and VEGF-C (16), VEGF-D
(4), VEGFR3(5) or LVD (14) [20–33,45,49–52,54–64,66,67]. Of these 16, three, three and six
included sufficient data in the form of 2x2 tables to be included in the aggregated analyses of
VEGF-C [20–24,27,30,33,50,55,58,61–64,66], VEGF-D [21,22,30], VEGFR3 [30,55,64] and
LVD [21,23,33,51,54,57] respectively, reporting on a total of 1889, 507, 556 and 677 patients.
Of the 30 studies included in the analyses, 29 used IHC for marker evaluation, while one
study used RT-PCR. The percentage of patients with positive markers and the cut-offs used for
marker evaluation varied extensively between studies (Table 1) and markers. For the evaluation
of IHC, some studies used a straight forward percentage of positive cells, while other studies
used a complex score (CS) consisting of several traits, including, but not limited to, percentage
of positive cells and staining intensity. For LVD the cut-offs ranged from6 to38 vessels per
high power field.
None of the authors prompted for supplementary data responded to the request.
Quality assessment
The scores from the quality assessment (QA) are given in Table 1 for the individual studies and
summarized in Table 2 for the overall scores for each marker. The overall quality scores (QS)
of papers reporting survival tended to be superior to papers reporting correlations with LNM.
This difference was largest for the dimension "results analysis" and probably due to the fact
that only one paper reporting associations with LNM explored their results in multivariable
models.
Meta-analysis
The results of the meta-analyses are summarized in Figs 2 and 3 and Table 3, while the individ-
ual univariate HRs, calculated or as reported, are given in Table 1.
VEGF-C: The overall HR for survival in patients expressing high tumor cell VEGF-C was
1.57 (95% CI: 1.34–1.84) across 18 studies using a random effects model and including 2107
patients (Fig 2A, Table 3). When using the trim and fill method to adjust for missing studies
Table 1. (Continued)
Study Year N Design Histology Stage Method Marker Positive Cut-off Survival LNM QS QS
HRe HR (95% CI) RR (95% CI) Surv LNM
Sun et al.[66] 2009 82 Retro All I-IV IHC LVD 50% 19.9 Surv 1.54(0.7–3.3) 0.67
Takanami et al.[33] 2006 77 Retro All I-IIIa IHC VEGF-C 59% 10% 2.70(1.3–5.8) 0.66
LVD 49% 25 4.11(1.1–4.5)
Yamashita et al.[69] 2010 117 Retro All I IHC VEGF-C 49% 10% HR 1.89(1.0–3.5) 0.82
Zhang et al.[28] 2011 65 Retro Adeno I-IV IHC LVD 49%% 10 Surv 4.91(3.4–7.1) 0.62
Zuo et al.[27] 2008 48 Retro All I-III IHC VEGF-C 69% CS 3.18(0.8–1.6) 0.48
Abbreviations: N, number; LNM, Lymphatic node metastasis; HR, hazard ratio; HRe, how the HR-estimate was obtained (HR = given in the text,
Surv = estimated from survival curve); RR, relative risk; QS, quality score; CS, complex score; VEGF, vascular endothelial growth factor; VEGFR,
vascular endothelial growth factor receptor; LVD, lymphatic vascular density; NG, not given.
doi:10.1371/journal.pone.0132481.t001
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the HR was 1.46 (95% CI: 1.23–1.73, Table 3). Subgroup analyses reporting on VEGF-C and
survival in 4 studies of adenocarinomas (n = 317) and 5 studies of stage I NSCLC (n = 542)
revealed HRs of 1.45 (95% CI: 1.04–2.03) and 1.56 (95% CI: 1.09–2.24), respectively (Fig 2A).
The overall RR for the association between VEGF-C and nodal metastasis was 1.66 (1.28–
2.15) across 15 studies using a random effects model and including 1889 patients (Fig 3A,
Table 2. Results of the quality assessment of the included studies bymarker. Maximal score for any given category is 1.
Scientific Laboratory Generalizability Results Overall
Design Methodology Analysis Score
VEGF-C Survival 0.7(0.5–0.8) 0.6(0.4–0.8) 0.7(0.4–1) 0.7(0.5–1) 0.7(0.5–0.8)
VEGF-D Survival 0.7(0.7–0.8) 0.7(0.5–0.8) 0.8(0.6–1) 0.7(0.7–0.8) 0.7(0.6–0.8)
VEGFR3 Survival 0.7(0.7–0.8) 0.7(0.6–0.8) 0.8(0.6–1) 0.8(0.7–0.9) 0.7(0.7–0.8)
LVD Survival 0.7(0.7–0.8) 0.6(0.5–0.7) 0.7(0.6–1) 0.7(0.4–0.8) 0.7(0.6–0.8)
VEGF-C LNM 0.7(0.5–0.8) 0.6(0.5–0.8) 0.7(0.4–1) 0.5(0.3–0.7) 0.6(0.5–0.8)
VEGF-D LNM 0.7(0.6–0.8) 0.6(0.5–0.8) 0.7(0.5–1) 0.5(0.4–0.7) 0.6(0.5–0.8)
VEGFR3 LNM 0.8(0.7–0.8) 0.7(0.6–0.8) 0.9(0.8–1) 0.6(0.5–0.7) 0.7(0.7–0.8)
LVD LNM 0.7(0.6–0.8) 0.6(0.5–0.7) 0.7(0.5–1) 0.4(0.1–0.5) 0.7(0.5–0.8)
Abbreviations: LNM, Lymphatic node metastasis; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; LVD,
lymphatic vascular density.
doi:10.1371/journal.pone.0132481.t002
Fig 2. Forest plots of the survival meta-analyses for; A) VEGF-C, B) VEGF-D, C) VEGFR3, D) LVD, Funnel plots showing the relationship between
the observed HR and the standard deviation in the survival meta-analyses for; E) VEGFR3, F) LVD. Abbreviations: VEGF, vascular endothelial growth
factor; VEGFR, vascular endothelial growth factor receptor; LVD, lymphatic vascular density; N, number: HR, hazard ratio.
doi:10.1371/journal.pone.0132481.g002
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Fig 3. Forest plots of the lymphatic node metastasis meta-analyses for; A) VEGF-C, B) VEGF-D, C) VEGFR3, D) LVD, Funnel plots showing the relationship
between the observed RR and the standard deviation in the lymphatic node metastasis meta-analyses for E) VEGF-C, F) LVD Abbreviations: VEGF,
vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; LVD, lymphatic vascular density; N, number; RR, relative risk.
doi:10.1371/journal.pone.0132481.g003
Table 3. Summarizing the aggregated analyses and their corresponding heterogeneity tests. Values for unadjusted, leave1out (test conducted with-
out the one study introducing the most heterogeneity) and adjusted (test conducted with the inclusion of studies assumedmissing in case of funnel
asymmetry).
Survival summary LNM summary
HR (95%CI) Q P TAU2 I2(%) H2 RR (95%CI) Q P TAU2 I2(%) H2
VEGF-C 1.57(1.34–1.84) 18.03 0.39 0 1.37 1.01 1.66(1.28–2.15) 40.47 <0.001 0.17 66.66 3
VEGF-C(leave1out) 1.62(1.38–1.91) 14.98 0.53 0 0 1 1.54(1.2–1.96) 32.52 <0.001 0.12 59.65 2.48
VEGF-C(adjusted) 1.46(1.23–1.73) 26.99 0.14 0.03 18.69 1.23 1.26(0.91–1.73) 76.53 <0.001 0.42 80.56 5.14
VEGF-D 0.81(0.43–1.52) 7.12 0.07 0.24 60.58 2.54 1.43(0.76–2.71) 5.96 0.05 0.23 74.49 3.92
VEGF-D(leave1out) 1.16(0.83–1.62) 1.73 0.42 0 0 1 1.13(0.84–1.53) 0.77 0.38 0 0 1
VEGF-D(adjusted) 1.22(0.57–2.62) 16.52 0.01 0.67 78.29 4.61 1.43(0.76–2.71) 5.96 0.05 0.23 74.49 3.92
VEGFR3 1.48(0.77–2.86) 12.88 0.01 0.39 79.07 4.78 1.71(1.34–2.18) 0.92 0.63 0 0 1
VEGFR3(leave1out) 1.98(1.46–2.68) 5.14 0.16 0.02 15.28 1.18 NA NA NA NA NA NA
VEGFR3(adjusted) 1.66(0.88–3.15) 14.85 0.01 0.4 76.23 4.21 1.56(1.27–1.92) 2.87 0.58 0 0 1
LVD 1.84(1.18–2.87) 32.27 0 0.28 72.95 3.7 2.24(1.13–4.46) 32.52 <0.001 0.62 86.47 7.39
LVD(leave1out) 1.58(1.17–2.13) 8.38 0.21 0.03 18.24 1.22 2.67(1.25–5.72) 23.47 <0.001 0.62 82.73 5.79
LVD(adjusted) NA NA NA NA NA NA 2.24(1.13–4.46) 32.52 <0.001 0.62 86.47 7.39
Abbreviations: HR, hazard ratio; RR, relative risk; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; LVD,
lymphatic vascular density; NA, not applicable; Q, test for heterogeneity; P, the p-value calculated for Q; TAU2, an estimate of the total amount of
heterogeneity; I2, the proportion of total variation in study estimates attributed to heterogeneity; H2, the total variability or within study variance.
doi:10.1371/journal.pone.0132481.t003
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Table 3). When using the trim and fill method to adjust for possible missing studies the RR was
1.26 (0.91–1.73).
VEGF-D: In this meta-analysis VEGD-D was neither found to be associated with survival
nor nodal metastasis in NSCLC patients.
VEGFR3: The overall HR for survival in patients expressing high tumor cell VEGFR3 was
1.48 (95% CI: 0.77–2.86) across 5 studies using a random effects model and including 747
patients (Fig 2C, Table 3). When using the trim and fill method to adjust for missing studies
the HR was 1.66 (95% CI: 0.88–3.15, Table 3). Another approach, leaving out the one study
introducing the most heterogeneity, revealed an overall HR for survival of 1.98 (95% CI: 1.46–
2.68, Table 3).
The overall RR for association between VEGFR3 and nodal metastasis was 1.71 (95% CI:
1.34–2.18) across 3 studies and including 556 patients (Fig 3C, Table 3). When using the trim
and fill method to adjust for possible missing studies the RR was 1.56 (95% CI: 1.27–1.92).
LVD: The overall HR for survival in patients expressing high levels of LVD in tumor was
1.84 (95% CI: 1.18–2.87) across 8 studies using a random effects model and including 849
patients (Fig 2D, Table 3). The trim and fill method did not suggest any missing studies and an
adjusted HR was therefore not calculated.
The overall RR for the association between LVD and nodal metastasis was 2.24 (95% CI:
1.13–4.56) across 6 studies and including 667 patients (Fig 3D, Table 3). The trim and fill
method did not suggest any missing studies and a adjusted RR was therefore not calculated.
Publication bias
Egger's test for survival yielded p-values as follows: VEGF-C 0.400, VEGF-D 0.146, VEGFR3
0.020, VEGF-C in adenocarcinomas 0.073, VEGF-C in stage I patients 0.892 and LVD 0.006.
This suggests significant publication bias in studies reporting on VEGFR3 and LVD and in the
subgroup-analyses of VEGF-C. The contour enhanced Funnel plot for VEGFR3 (Fig 2E) sug-
gests that the missing studies may be in an area of high statistical significance, but due to the
low number of studies included, the Funnel plot has to interpreted with diligence. The contour
enhanced Funnel plot for LVD (Fig 2F) suggests that the missing articles are those with low
standard error of the effect estimate.
Egger's test for nodal metastasis yielded p-values as follows: VEGF-C<0.001,
VEGF-D0.169, VEGFR3 0.375 and LVD 0.004. This suggests significant publication bias in the
studies reporting on VEGF-C and LVD. The contour enhanced Funnel plot of VEGF-C (Fig
3E) indicates a strong positive publication bias. The contour enhanced Funnel plot of LVD (Fig
3F) indicates the lack of larger studies and a possible positive publication bias.
Statistical considerations
The results of the aggregated analyses were obtained using the results reported in univariate
analyses only. Some information can potentially be lost from studies reporting only multivari-
ate results with inadequate data to reconstruct the univariate analysis. Multivariate data are
only valid in their own multivariate system. Including multivariate data in the aggregated anal-
ysis provides increased numbers of patients at the cost of increased heterogeneity. This may be
tolerated if all included studies are adequately large and includes the same, or approximately
the same, variables in their multivariate models. In this meta-analysis the number of patients
in the included studies ranged from 48 to 335 and the variables included in the different multi-
variate models varied (data not shown). Thus making the inclusion of data from multivariate
analyses in the meta-analysis a dubious venture.
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Heterogeneity is difficult to avoid when conducting meta-analyses based on marker data, as
there exists no consensus on how such studies should be conducted. Among the included stud-
ies (Table 1), all but one were retrospective and all but one used IHC to detect the protein
markers. Moreover, they differ largely with respect to selected antibodies, choice of cut-offs for
the different markers and in the percentage of positive cases. The European Lung Cancer
Working Party has proposed a quality scale for biological prognostic factors for lung cancer,
but few studies adhere to this scale [34]. We utilized this scale to rate the included studies
(Table 2). Mixed model approaches (data not shown) utilizing histology, stage, method, per-
centage of positives cases, cut-offs or quality scores as static modifiers were attempted, but
none of these contributed to the overall model design and thus were rejected.
The present meta-analysis was restricted to articles published in the English language. This
could introduce a positive selection bias as there is a tendency for positive studies to be pub-
lished in English while negative studies more often are published in the authors native language
[71]. Indeed, testing in the current meta-analyses suggested significant publication bias for
studies reporting survival based on VEGFR3 and LVD and for LNM based on VEGF-C and
LVD. Based on this the results of this meta-analysis have to be interpreted carefully and should
be confirmed in larger trials.
Obtaining individual patient data for meta-analysis would theoretically help to define the
role of lymphangiogenic markers by adjusting for the same confounders before data aggrega-
tion across all included studies [72]. However, this does not appear to be feasible as all authors
were prompted by e-mail for additional information, but none of them replied.
Discussion
Summary of the meta-analyses
This is, to our knowledge, the most comprehensive structured review with meta-analysis of
VEGF-C, VEGF-D and LVD in NSCLC. One meta-analysis has previously reported on
VEGF-C and VEGFR3 and their association with survival in NSCLC [73]. Zhan et al. published
the aggregated results of 8 studies reporting on VEGF-C and 4 studies allegedly reporting on
VEGFR3 (The authors considered Flt1 to represent VEGFR3 –Flt1 is in fact equal to VEGFR1,
while Flt4 is equal to VEGFR3) in 2009. They found the aggregated results of the studies
reporting on VEGF-C and VEGFR3 to be non-significant in NSCLC [73]. Further, Wang et al.
reviewed the aggregated results of 10 studies reporting on LVD and survival in NSCLC patients
in 2012. They included multivariable adjusted results and in addition one study reporting
VEGFR3 in tumor cell cytoplasm [16]. Since 2009 several studies on VEGF-C, VEGF-D,
VEGFR3 and LVD have been published. This current meta-analysis correlates VEGF-C,
VEGFR3 and high levels of LVD with nodal metastasis in NSCLC patients and identifies high
VEGF-C (HR 1.57 95% CI: 1.34–1.84) and high levels of LVD (HR 1.84 95% CI: 1.18–2.87) as
significant prognostic markers of poor survival.
The VEGF-C/-D/R3 axis in relation to survival and lymphatic metastasis
in NSCLC
VEGF-C, VEGF-D and their corresponding receptor VEGFR3 are well-known and strong lym-
phangiogenic markers [9,10,74]. In an extensive mapping of the VEGF-C/VEGFR3 axis in
lung adenocarcinoma tumors, cell-lines and animal models Su. et al. found high expression of
both VEGF-C and VEGFR3 to be correlated with nodal metastasis whereas expression was low
for early-stage disease [11]. Further, NSCLC cell-lines over-expressing the VEGF-C/VEGFR3
axis showed increased migration, and, when introduced into xenograft models, more
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frequently formed lung metastases, compared to NSCLC cell-lines where VEGF-C/VEGFR3
signaling had been abrogated [11]. He et al. investigated the interaction between the lung can-
cer cell-line LNM35, which expresses high levels of VEGF-C, and lymphatic endothelial cells
(LECs). They found VEGF-C to induce lymphatic vessel destabilization and enlargement of
collecting lymphatic vessels, which further lead to passage of tumor clusters to sentinel lymph
nodes [14]. In squamous cell carcinoma of the skin, Hirakawa et al. showed that VEGF-C over-
expressing tumors maintained their lymphangiogenic profile after arrival in the sentinel lymph
nodes [13]. Building on this, Liersch et al. found melanoma xenografts over-expressing
VEGF-C to instigate lymphatic vascularization in the sentinel lymph nodes before the presence
of metastatic cells could be detected [12]. These latter results are supported by a study on
human surgical specimen (oral squamous cell carcinoma) demonstrating an increased number
of high endothelial venules and lymphatic vessels without detecting metastatic cells [19]. How-
ever, in a recent study Nwogu et al. investigated the presence of nodal micro-metastases in
pStage I and II NSCLC patients using conventional H&E, IHC and RT-PCR on resected lymph
nodes. They found that 35/40, 33/40 and 16/40, respectively, were N0, indicating that conven-
tional H&E and IHC might not be adequately sensitive to detect metastatic cells. They also
demonstrated a strong correlation between the presence of nodal micro-metastases and the
expression of VEGF-A, VEGF-C, VEGF-D and VEGFR3 in the lymph nodes [75]. Niki et al.
isolated total RNA from 60 surgically resected lung adenocarcinomas of which 27 had lymph
node metastasis and found only weak correlations between lymph node metastasis and
VEGF-C. However, a high ratio VEGF-A,-B or -C to VEGF-D was associated with lymph node
metastasis and the authors proposed that VEGF-D may have a regulatory role in tumor lym-
phangiogenesis [60]. Clearly, RNA expression does not necessarily translate to protein expres-
sion and it can be argued that a high ratio of VEGF-A, B or -C RNA to VEGF-D RNA simply
represents over-expression of these molecules rather than VEGF-D having a regulatory role.
The results of this meta-analysis indicate that VEGF-C is a prognostic factor for lymph node
metastasis (HR 1.66 95% CI: 1.28–2.15) and survival (HR 1.57 95% CI: 1.34–1.84) in NSCLC
patients, and further, that high expression of VEGFR3 is a prognostic factor for lymph node
metastasis (HR 1.71 95% CI: 1.34–2.18)
LVD in relation to survival and lymphatic metastasis in NSCLC
LVD describes the density of lymphatic vessels in the tumor micro environment [76]. In lym-
phovascular invasion (LVI) is an established adverse prognostic factor in NSCLC describing
the presence of cancer cells within the lymphovascular space. LVI was recently reviewed by
Mollberg et al. for stage I NSCLC [15]. There is controversy regarding the clinical implications
of LVD in NSCLC. As of today, no consensus for the evaluation of LVD exists. This results in
LVD being evaluated using several antibodies including D2-40, podoplanin, and VEGFR3 and
by several techniques including the single most positive high-powered field (hot-spot), the
invasive tumor front, the tumor center and combinations of these. Our systematic approach
identified 12 studies reporting survival and 14 studies reporting associations with LNM in
NSCLC patients. The studies varied in methodological approach with some evaluating the
presence of LVD in hot-spots and some in random areas, either within the central tumor, in
the invasive tumor front, a mix of different areas or location not given. This lead to a consider-
able difference in cut-offs used for high/low vessel count (summarized in Table 1). Unfortu-
nately the number of studies utilizing the same methodology was too small to warrant sub-
group analyses. Nevertheless, our meta-analysis identified high LVD-levels as a marker of poor
prognosis (HR 1.84 95% CI 1.18–2.87) and LNM (HR 2.24 95% CIT 1.13–4.46) in NSCLC
patients. Interestingly, Sun et al. found peritumoral LVD to be linked to survival while
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intratumoral LVD was not, suggesting this to be of interest for future studies [66]. This has an
intuitive ring to it, as it seems logical that tumor cell migration to lymph nodes only can occur
in functional lymphatic vessels mostly found in the tumor periphery and not in intratumoral
lymphatic vessels that tend to be collapsed and non-functional. However, there is evidence sug-
gesting that tumor cells may utilize the latter approach when entering the lymphatic system
[76]. Renyi-Vamos et al. stratified patients based on low and high angiogenic activity in
tumors, and found peritumoral LVD to significantly worsen the prognosis of those in the high
angiogenic group [63]. In oral squamous carcinoma, LVD in sentinel nodes was elevated
regardless of the presence of metastatic cancer cells, and correlated to tumor VEGF-C expres-
sion, suggesting an interplay between tumor and lymph node prior to the arrival of cancer cells
[19]. In a recent meta-analysis, including 1044 breast cancer patients, LVD was correlated to
LNM, but not to other known breast cancer traits [77]. Results of this meta-analysis coincide
with the published literature of other cancer entities and suggests LVD as a prognostic marker
for survival and LNM in NSCLC patients.
Targeting lymphatic metastasis in the treatment of NSCLC
With the availability of small-molecule inhibitors and antibodies that could potentially target
tumor lymphangiogenesis it seems appropriate that this treatment should be offered patients
to whom it may prove beneficial. The challenge will be to select the correct patients. As pointed
out in the xenograft model from He et al. timing seems to be of importance. In their model, no
benefit of anti-VEGFR3 antibodies was observed when administered after the development of
lymphangiogenic networks [14]. Evidently, results from murine models should be carefully
evaluated before applied to actual human patients, but bad timing appears to be a feasible
explanation for part of the moderate or lacking effects reported after a number of anti-angio-
genic and also anti-lymphangiogenic approaches [78]. Interestingly, Tamura et al. have investi-
gated serum VEGF-C levels of NSCLC patients with and without LNM [67]. They found high
levels of VEGF-C to be associated with LNM with positive and negative predictive values of 70
and 77.3 respectively and that the addition of serum VEGF-A, serum matrix metalloproteinase
9 or CT-images further improved the diagnostic properties of the test [25,67,79]. These results
were supported by the findings of Daly et al. in 2014 [80].
The results of this meta-analysis indicate that targeting lymphangiogenesis could prove ben-
eficial for selected sub-groups of NSCLC patients. With timing being essential, theoretically,
the best use of lymphangiogenic inhibitors could be in the adjuvant setting and for patients
with low grade tumors in whom lymphatic node metastases have yet to develop. Obviously, the
use of any drug in the adjuvant setting must be considered carefully as a proportion of patients
have been cured of their cancer and will not benefit from further treatment. The studies linking
serum levels of VEGF-C to nodal metastasis are especially interesting. These results indicate
that NSCLC patients with no acknowledgeable LNM and high serum VEGF-C might be at risk
and may be the patients who will benefit from anti-lymphaniogenic. According to the recent
study by Daly et al. their group is setting up animal models with a plan to further elucidate
their findings on serum-VEGF-C levels and LNM, hopefully culminating in a clinical trial; the
results of these subsequent studies, will be very interesting [80].
During the past decade, cancer immunology has experienced a renaissance through the
understanding of the immune check-points and the development of immune check-point
inhibitors [81–83]. This important clinical research effort which initially succeeded in mela-
noma is now benefiting a wide host of other tumor groups [81–83]. Evidence indicates lym-
phangiogenic markers to mediate a profound impact on the immune system. Tumors
expressing lymprhangiogenic factors are believed to alter the micro-environment in the lymph
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nodes, hence preparing them for the arrival and harboring of metastatic cells [12,13,19]. In
fact, active lymphangiogenic processes may down-regulate immune responses and thus be
partly responsible for the poor effect the immune system shows on most malignant tumors
[84]. However, once the tumor associated lymphatic network is established, little is known of
its role regarding the tumor immune responses. Tumor antigens must reach antigen presenting
cells in order to induce a T-cell mediated immune response, and in this process the presence
of, or interaction with, tumor-induced lymphatics may be of importance [84].
Conclusions and implications for research
Our results indicate a connection between lymphangiogenic markers, LVD, LNM and survival
in NSCLC. Nevertheless, it is apparent that lymphangiogenic factors cannot explain the full
extent of LNM. Alternative pathways exist for cancer cells to recruit and invade lymphovascu-
lar structures, such as vessel co-option and vascular mimicry [85].
Further studies are warranted to evaluate the results of this meta-analysis and it would be
highly interesting to see studies combining expressions of lymphangiogenic markers in pri-
mary tumor tissues and metastatic lymph nodes. In addition, we believe that studies investigat-
ing this intricate relationship between tumor-lymphangiogenesis and immunology will prove
beneficial, not only for our understanding of these principles, but also for patients who could
benefit from combined therapeutic approaches.
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